Eugia Pharma Receives USFDA Approval for Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL, 1 mL Single-Dose Vial and 150 mg/mL, 1 mL Prefilled Syringe

Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market:

Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL, 1 mL Single-Dose Vial
FDA approved 8/22
Refer to package insert for full prescribing information.

Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL, 1 mL Prefilled Syringe
FDA approved 8/31
Refer to package insert for full prescribing information.

Indications for this product include:

• Indicated for use by females of reproductive potential to prevent pregnancy.